Itopride, a novel prokinetic agent is unique and different from the available prokinetics because of its dual mode of action and lack of significant drug interaction potential. Itopride is a newly developed prokinetic agent, which enhances gastric motility through both anti-dopaminergic and anti-acetylcholinesterage actions. It is best candidate for Gastro Esophageal Reflux Disease. Itopride 50mg can be given thrice in a day for Treatment of GERD. By developing the sustain release formulation of Itopride hydrochloride, the frequency of drug can be reduce to once only to obtain good therapeutic response. The prepared formulation is usually taken on an empty stomach about an hour before meals. Sustained release tablet of Itopride Hydrochloride was prepared by using combination of HPMC grade as matrix forming material. The influence of amount of Hydroxypropyl Methylcellulose K15M and Hydroxypropyl Methylcellulose K100M on release of Itopride hydrochloride was studied using Central composite design. The optimized Formulation FB7 had given prolonged drug release up to 24 hr. It also had desired drug release kinetics and it was found to be stable after 1 month at accelerated conditions.

In the present investigation, solid dispersion of olanzapine has been prepared to improve its solubility. Further, using solid dispersion, mouth dissolving tablet was prepared to overcome the problem of swallowing. A Simplex Lattice design was applied using three factors, i.e. superdisintegrants like croscarmellose sodium(X1) crospovidone(X2), and sodium starch glycolate(X3) in tablet formulation. Disintegration time, Wetting time, Water absorption, T50 (Time required to 50% drug release) and Q10 (percentage of drug released in 10 min.) taken as responses. Solid dispersion showed significant enhancement in solubility of olanzapine. For mouth dissolving tablet, batch containing 5% croscarmellose sodium alone had minimum disintegration time (44 sec.) and faster drug release(T50: 40 sec) compared to other batches.

To develop sustained release matrix tablet of Tramadol HCl that deliver drug for 24 hr and to be taken once in a day. Drug having high solubility and relatively shorter half-life suggests its suitability for an extended formulation. If it is formulated by conventional tablets, it will require multiple daily administrations which ultimately results into inconveniency to the patients and possibility of reduced compliance with prescribed therapy. Also fluctuation in plasma drug concentration leads to exaggerated side effects, this all limitations can be minimized by adopting extended release formulation. To reduce the frequency of administration and to improve the patient compliance, Once in a day sustained release formulation is desirable. It describes the influence of the concentration of HPMC K4M, HPMC K15M and HPMC K100M on Tramadol HCl sustained release formulations using box-behnken design.These Polymers were selected as an independent variables. Drug release after 8 hr, 12 hr and 16 hr were selected as a dependent variables. Optimized formulation found by similarity and dissimilarity factor follow zero order kinetic with non-fickian diffusion as a drug release mechanism.

Metoprolol Tartrate is a -blocker drug indicated for the treatment of angina, prevention of myocardial infarction, Essential hypertension; It has low bioavailability of about 40% due to hepatic metabolism. The purpose of this research was to improve the bioavailability by preparing a fast dissolving tablet using superdisintegrants method. Because pregastric absorption of drug improves bioavailability, gives rapid onset of action when needed."